Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to
evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination
with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with
liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair
proficient/microsatellite stable (pMMR/MSS).